Indonesian Markets Brace for Tariff Turmoil After Weeklong Break
Stocks, bonds and currency markets will resume trading for the first time since March 27, after the nation observed the Eid al-Fitr holidays, over which period the iShares MSCI Indonesia exchange-traded fund has fallen about 8%. During the break, US President Donald Trump's tariffs — and a subsequent retaliation by China — trigged a sharp selloff in risk assets, leading to a rout across Asia.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Canadian dollar gives up much of its weekly gain as trade deal prospects ebb
By Fergal Smith TORONTO (Reuters) -The Canadian dollar weakened against its U.S. counterpart on Friday as optimism waned that Canada would reach a trade deal with the United States before an August 1 deadline and ahead of a Bank of Canada interest rate decision. The loonie was 0.5% lower at 1.3710 per U.S. dollar, or 72.94 U.S. cents, after trading in a range of 1.3639 to 1.3725. For the week, the currency was on track to gain 0.1%. The United States may not reach a negotiated trade deal with Canada, U.S. President Donald Trump said, suggesting his administration could set a tariff rate unilaterally. Canada sends about 75% of its exports south of the border. "Markets are now pricing in a lower chance of a U.S.-Canada deal before August 1," said Kevin Ford, FX & macro strategist at Convera. "With tariff talks likely dragging on past next Friday, the CAD has bounced back above 1.37." The Bank of Canada will hold its overnight interest rate steady at 2.75% on July 30 for the third consecutive meeting thanks to a recent rise in inflation and a fall in unemployment, according to a Reuters poll of economists that still found many expect at least two more cuts this year. The U.S. dollar advanced against a basket of major currencies after Trump on Thursday said that he did not intend to fire Federal Reserve Chair Jerome Powell, as he has frequently suggested he could. The price of oil, one of Canada's major exports, fell 1.4% to $65.11 a barrel on negative economic news, including data that showed new orders for key U.S.-manufactured capital goods unexpectedly fell in June. Canadian bond yields moved lower across the curve, with the 10-year down 4.1 basis points at 3.515%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
19 minutes ago
- Bloomberg
Euro-Zone Growth to Stall as Short-Lived Trade Boost Unwinds
Key euro-area output data next week are expected to show the economy stagnated in the second quarter, the flipside of tariff-related frontloading that provided an temporary boost at the start of the year. Economists in a Bloomberg poll expect Wednesday's figures to show gross domestic product remained flat in the three months through June, after 0.6% expansion in the first quarter. That performance was lifted by a sudden increase in trade — particularly visible in Irish figures — before Donald Trump's expected announcement of global import duties.
Yahoo
36 minutes ago
- Yahoo
Pharma's turbo spending spree on US manufacturing
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Investments in U.S. drug manufacturing are skyrocketing. Pharma giants everywhere have announced massive, multi-year deals to build and expand facilities across the country as several market factors make the U.S. a favorable destination for producing branded drugs. The looming threat of U.S. tariffs remains a motivator for companies from around the globe. Earlier this month, President Donald Trump said tariffs as high as 200% on pharma products would be introduced 'very soon.' Other industry shifts, including the growing GLP-1 market and the demand for skilled workers in pharma's tech-heavy manufacturing environment, are also tipping the scales toward the U.S. Amid the investment boom, tens of billions of dollars are pouring into manufacturing hubs like Raleigh, North Carolina, and generating thousands of job openings for engineers, R&D personnel, operations professionals and more. Here's a look at the latest companies to hop on the U.S. manufacturing bandwagon. AstraZeneca makes its largest-ever single facility investment AstraZeneca joined the $50 billion club this month when it announced a sprawling manufacturing and R&D investment in the U.S. The size of the investment matches the other leading pledges from pharma companies this year — including Roche, Johnson & Johnson and Eli Lilly — to each pump $50 billion or more into U.S. facilities. CEO Pascal Soroit acknowledged that tariffs played a part in the U.K.-based company's decision to pump up its U.S. operations in a recent interview with Fortune, but also noted that Europe is 'losing ground' as a drug production destination by focusing on 'social benefits and managing costs.' AstraZeneca's plan includes $4 billion for a drug substance facility in Virginia — its largest single-facility manufacturing investment in the world. But the $50 billion in funds will stretch across the country and include an R&D expansion in Maryland, a continuous manufacturing expansion in Indiana, a next-generation cell therapy facility in Texas, a 'state of the art' R&D center in Massachusetts' biotech hub at Kendall Square and more. The American market for drugs also plays a starring role in the company's broader ambitions. All told, AstraZeneca aims to boost its total revenue from the $54 billion-mark it hit in 2024 to over $80 billion by 2030 — half of which it expects to be generated in the U.S., the company said. Biogen pours more into North Carolina Biogen is broadening its manufacturing footprint in North Carolina. The company said it will invest $2 billion into two campuses in the state's Research Triangle Park, Biogen's current hub for manufacturing. The fresh funds will expand Biogen's capacity for multiple modalities, including antisense oligonucleotides, while modernizing its operations with automation and AI. Biogen is still working to move past its Aduhelm debacle. The Eisai-partnered Alzheimer's drug notched a historic approval in 2021 but was later pulled from the market amid cost and efficacy controversies. Its other Alzheimer's treatment Leqembi has had a stronger showing on the market and has steadily risen in sales since last year. But Biogen has also been in cost-cutting mode since 2023 and expects revenue to decline this year. Going forward, the company is leaning on its pipeline, including treatments for Dravet syndrome, a rare form of epilepsy, to set the stage for future growth. Its latest manufacturing investment adds to the $10 billion it has funneled into North Carolina since setting up shop at Research Triangle Park in 1995. Thermo Fisher snags Sanofi facility to boost fill-finish chops Thermo Fisher Scientific is expanding its production prowess with the help of a growing Sanofi partnership. The companies said this month that Thermo Fisher is snapping up a sterile, fill-finish manufacturing site from the French pharma for an undisclosed sum. The move comes amid higher-than-expected profit last quarter for Thermo Fisher, one of the pharma industry's key suppliers of clinical research services and equipment. The new digs will help Thermo Fisher 'strengthen' its U.S. manufacturing capabilities for the broader pharma industry, the company stated. The latest move is also a part of the four-year, $2 billion commitment to U.S. manufacturing Thermo Fisher announced in April. Recommended Reading Tracking a moving target: Drugmakers brace for a looming tariff impact
